Atlas Trials

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Clinical trial NCT01426334 · TERMINATED

Trial details

NCT number
NCT01426334
Sponsor
National Cancer Institute (NCI)
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Accelerated Phase Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous LeukemiaRelapsing Chronic Myelogenous Leukemia
Start date
2011-09-01
Primary completion
2012-06-01
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.